Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom

Br J Haematol. 2019 Mar;184(6):1040-1043. doi: 10.1111/bjh.15234. Epub 2018 Apr 20.

Authors

Bassit Malik¹, Graham P Taylor¹

Affiliation

¹ Section of Virology, Imperial College London, Norfolk Place, London, UK.

PMID: 29676441
DOI: 10.1111/bjh.15234

No abstract available

Keywords: ATL; HTLV-I; antenatal; prevention; screening.

Publication types

Letter

MeSH terms

Cost-Benefit Analysis
Female
Human T-lymphotropic virus 1 / pathogenicity*
Humans
Incidence
Leukemia-Lymphoma, Adult T-Cell / diagnosis*
Leukemia-Lymphoma, Adult T-Cell / economics*
Prenatal Diagnosis / economics*
United Kingdom